(Q37912288)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819633%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819633%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819633%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Piotr Ozierański

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819633%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Lawrence King

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819633%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

8 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819633%20AND%20SRC:MED&resulttype=core&format=json

Health Economics, Policy and Law

9 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819633%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819633%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819633%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

175-195

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819633%20AND%20SRC:MED&resulttype=core&format=json

Should patient groups accept money from drug companies? No.

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

Drug reimbursement in Finland—a case of explicit prioritising in special categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

Can patients assess the quality of health care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

Partial progress: governing the pharmaceutical industry and the NHS, 1948-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

The pharmaceutical industry as a political player.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

Should patient groups accept money from drug companies? Yes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

Selling sickness: the pharmaceutical industry and disease mongering

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

Key opinion leaders: independent experts or drug representatives in disguise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: entanglement

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

Deconstructing media coverage of trastuzumab (Herceptin): an analysis of national newspaper coverage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

Relationships between the pharmaceutical industry and patients' organisations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

Thick prescriptions: toward an interpretation of pharmaceutical sales practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

Co-operation between patient organisations and the drug industry in Finland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

How NICE may be outflanked.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

Should the drug industry work with key opinion leaders? No.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

Conflicts of interest. WHO and the pandemic flu "conspiracies".

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

Moderate pandemic, not many dead--learning the right lessons in Europe from the 2009 pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

Should the drug industry work with key opinion leaders? Yes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

[Organization, functioning and expectations of organizations representing patients. Survey of key informants]

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

7 January 2021

Herceptin and early breast cancer: a moment for caution

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

7 January 2021

How pharmaceutical industry funding affects trial outcomes: causal structures and responses

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

7 January 2021

In whose interest? Relationships between health consumer groups and the pharmaceutical industry in the UK

1 reference

https://api.crossref.org/works/10.1017%2FS1744133111000168

7 January 2021

10.1017/S1744133111000168

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21819633%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference